Evidence map›Paper›PMID 42574094›Full record

ArticleExperimental and clinical psychopharmacology2026

The use of behavioral economic demand in human abuse potential assessment: A review and recommendations for future testing.

Justin C Strickland, Derek D Reed, Mikhail N Koffarnus, Samuel F Acuff, Brett W Gelino, Madison E Graham, Brent A Kaplan, Alexandra Johansen, Zachary Pierce-Messick, Matthew L Banks and 6 more

Abstract read
In one paragraph

Article in Experimental and clinical psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Justin C StricklandKahlert Institute for Addiction Medicine, University of Maryland, Baltimore.ORCID 0000-0003-1077-0394
Derek D ReedInstitutes for Behavior Resources, Inc.ORCID 0000-0002-5854-3425
Mikhail N KoffarnusDepartment of Family and Community Medicine, University of Kentucky.
Samuel F AcuffRecovery Research Institute, Department of Psychiatry, Massachusetts General Hospital.
Brett W GelinoDepartment of Psychiatry, Robert Wood Johnson Medical School, Rutgers University.
Madison E GrahamDepartment of Applied Behavioral Science, University of Kansas.
Brent A KaplanCodedbx.
Alexandra JohansenDepartment of Psychology, University of Kentucky, College of Arts and Sciences.
Zachary Pierce-MessickDepartment of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine.
Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University.
S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University.
David N KearnsPsychology Department, American University.
Dominic ChiapperinoCenter for Drug Evaluation and Research, Food and Drug Administration, United States Department of Health and Human Services.
Chad J ReissigCenter for Drug Evaluation and Research, Food and Drug Administration, United States Department of Health and Human Services.
Neil B VarshneyaCenter for Drug Evaluation and Research, Food and Drug Administration, United States Department of Health and Human Services.
Steven R HurshInstitutes for Behavior Resources, Inc.

Funding

Intramural FDA HHS FD999999US Department of Health and Human Services; Food and Drug Administration
6 · The paper itself

Abstract

A key step in the regulatory evaluation of new chemical entities is the assessment of their abuse potential. Human abuse potential (HAP) studies provide insights into the likelihood that new chemical entities have the potential for intentional, nonmedical use and therefore should be considered for greater regulatory control. Behavioral economic demand methods are proposed as a complementary method to improve the resolution of abuse liability testing. These procedures are posited to provide scalar, rank-ordered comparisons of abuse potential that are comparable across drugs and to better model real-world contexts in which constraint and cost influence drug-taking potential. The current review considers the applicability of behavioral economic demand methods to HAP testing frameworks. We review existing studies that have applied procedures broadly consistent with HAP testing and integrated demand procedures to measure abuse potential and/or a drug reinforcement. Procedural details and the demand methods implemented are reviewed toward the goal of informing the methods for applying demand testing in the HAP study framework and the existing gaps in defining those methods. Ultimately, efforts to improve the sensitivity and resolution of assays to detect and differentiate abuse potential stand to improve public health by concentrating efforts on the adequate control of drugs that pose risk while minimizing the restrictions on those with a lower abuse potential to maximize their clinical utility. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

Identifiers

PMID42574094
PMCPMC13519940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.